A study of hetrombopag to help platelets recover after stem cell transplant for neuroblastoma
Treatments studied
Part of Cancer clinical trials.
This trial tests if a drug called hetrombopag can help children with neuroblastoma recover their platelet counts more quickly after their own stem cells are transplanted. It aims to reduce the time needed for platelet engraftment and lower the risk of bleeding.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are under 18 years old.
- You have been diagnosed with neuroblastoma.
- You are healthy enough for daily activities (ECOG score 0–2).
- This is your first time receiving your own stem cells as a transplant.
- You or your guardian can agree to join and sign a consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if romiplostim, a drug that helps the body make platelets, can speed up platelet recovery after a special type of stem cell transplant from a half-matched donor. It may help reduce bleeding risk during the recovery period.
This study tests whether a drug called hetrombopag can help your immune system stop attacking your platelets, so your platelet count stays up even after stopping the drug. It's for people with ITP who responded well to hetrombopag but want to see if they can stay in remission without it.
This Phase 2 study tests eltrombopag to help people with low platelet counts caused by chemotherapy (which can increase bleeding risk). It looks at whether raising platelets can reduce bleeding problems and help you stay on track with care.
This Phase 2 trial studies herombopag to raise very low platelet counts caused by chemotherapy and reduce bleeding risk. It may help people whose platelet levels stay too low even after prior standard attempts like rhTPO or IL-11.
This trial tests a new platelet-raising medicine, avatrombopag, in children with ITP who have already tried eltrombopag. It aims to see if switching to avatrombopag can safely increase platelet counts and reduce bleeding.
This trial tests a medication called Herombopag to raise platelet counts in adults aged 60 or older with immune thrombocytopenia (ITP). The goal is to see if it is safe and effective for this age group.
Hear when a new Neuroblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.